1Kalon KL,Joan LP, William BK. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol, 1993,22 (Suppl A):6A-13A.
2Hung YT, Cheug NT, Ip S. Epidemiology of heart failure in Hong Kong,1997. Hong Kong Med J, 2000,6:159-162.
3Packer M, Coats AJS, Fowler MB, et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001, 344:1651-1658.
4Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J, 2001, 22: 1527-1561.
5Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2001, 104:2996-3007.
6Nohria J，Am Heart J，1999年，137卷，1028页
7Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
8Hamroff G,Blaufarb I,Mancini D,et al.Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treat with angiotensin-converting enzyme inhibitors for heart failure[].Journal of Cardiovascular Pharmacology.1997
9Krombach RS,Clair MJ,Hendrick JW,et al.Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns[].Cardiovascular Research.1998
10Baruch L,Anand I,Cohen IS,et al.Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patient with heart failure[].Circulation.1999
5Francis G S, Goldsmith S R, Levine T B, et al. The neurohumorial axis in congestive heart failure. Ann Interm Med, 1984, 101 (3):370.
6The CONSENSUS Tiial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Surival Study (CONSENSUS) . N Engl J Med,1987,316:1249.
7Francis G S. Comparison of neuroendocirne activity in patients with left ventricular dysfunction with or without congestive heart failure(SOLVD) . Circulation,1990,82.. 1724.
8Vantrimpont P, Rouleau J L, Wun C, et al . For the SAVE Inves-tigatiuon. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement(SAVE) study. J Am Coll Cardiol,1997,29:229.
9Witherow F N, Heimy A, Webb D J. et al. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation, 2001,104 (18) : 2177.
10Cohn J N, Tognomi G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Mcd,2001,345 : 1667.
